Radiocontrast-induced renal failure.
Review of the literature concerning contrast-induced renal dysfunction shows that the currently used agents are remarkably safe with careful patient selection. Clinically apparent kidney failure after their use is essentially nonexistent in those without preexistent renal insufficiency. The incidence rises rapidly in those with azotemia from any cause, however, and diabetic persons with nephropathy are perhaps at special risk. Vigorous volume expansion is possibly effective as a preventive measure and may attenuate adverse effects in those in whom postcontrast dysfunction occurs. New agents are becoming available. It is not yet known if these will prove safer or cost-effective. They have some experimentally demonstrated and theoretic advantages over the presently used agents.
D058186:Acute Kidney Injury / Q000139:chemically induced*; D003287:Contrast Media / Q000009:adverse effects*; D005260:Female; D006801:Humans; D007468:Iodopyracet / Q000009:adverse effects / Q000031:analogs & derivatives*; D008875:Middle Aged; D014567:Urography
D003287:Contrast Media; C007505:diodonmorpholide; D007468:Iodopyracet